Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Short Interest Down 72.6% in July

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the target of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 7,595 shares, a decline of 72.6% from the July 15th total of 27,721 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

Laboratorios Farmaceuticos Rovi Stock Performance

Shares of OTCMKTS:LABFF opened at C$67.17 on Thursday. Laboratorios Farmaceuticos Rovi has a 1 year low of C$65.86 and a 1 year high of C$67.17. The business has a fifty day moving average price of C$65.79 and a two-hundred day moving average price of C$65.84.

Laboratorios Farmaceuticos Rovi Company Profile

Laboratorios Farmacéuticos ROVI SA is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.

ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology.